{"transactions":[{"id":2647604,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137683,"kind":"person","name":"Carrera Eric","position":1,"cik":"0001657726","reported_name":"Carrera Eric","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former officer"}}],"security":"Warrants","published_at":"2021-07-01T19:52:16.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":30000,"price":1,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Carrera served as the Issuer's Senior Vice President of Finance and Business Development until the closing of the business combination."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the \"Issuer\"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Carrera served as the Issuer's Senior Vice President of Finance and Business Development until the closing of the business combination."}],"balance_after":30000,"derivative":{"exercise_price":11.5,"exercise_date":"2021-07-30","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-21-015901","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657726/000149315221015901/ownership.xml","form_type":"4"}},{"id":4097927,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137683,"kind":"person","name":"Carrera Eric","position":1,"cik":"0001657726","reported_name":"Carrera Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2018-01-17T17:21:17.000Z","date":"2018-01-15","kind":"other","acquired":false,"shares":8330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 8,330 shares held by Mr. Carrera were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 8,330 shares held by Mr. Carrera were forfeited since the underwriters did not exercise their overallotment option in the Company's initial public offering."}],"balance_after":54701,"source":{"system":"sec-edgar","filing":"0001615774-18-000384","document":"s108739_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657726/000161577418000384/s108739_form4.xml","form_type":"4"}},{"id":4142120,"issuer":{"id":8108,"kind":"organization","name":"Ensysce Biosciences, Inc."},"owners":[{"id":137683,"kind":"person","name":"Carrera Eric","position":1,"cik":"0001657726","reported_name":"Carrera Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior Vice President"}}],"security":"Common Stock","published_at":"2017-12-05T18:56:14.000Z","date":"2017-12-05","kind":"other","acquired":false,"shares":1465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 1,465 shares held by Mr. Carrera were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"As contemplated by the securities subscription agreement between the reporting person and the Company, 1,465 shares held by Mr. Carrera were forfeited upon consummation of the Company's initial public offering for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an aggregate of 8,330 shares held by Mr. Carrera that are subject to forfeiture to the extent that the underwriters' overallotment option in the Company's initial public offering is not fully exercised."}],"balance_after":63031,"source":{"system":"sec-edgar","filing":"0001144204-17-062469","document":"tv480819_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1657726/000114420417062469/tv480819_4.xml","form_type":"4"}}]}